lovotibeglogene autotemcel (LYFGENIA)
lovotibeglogene autotemcel is an FDA-licensed reference biologic from Genetix Biotherapeutics Inc.. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2023
Reference approved
Reference product
LYFGENIA lovotibeglogene autotemcel
Genetix Biotherapeutics Inc.
- Approved
- Dec 08, 2023
- Marketing
- Rx
- Center
- CBER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for lovotibeglogene autotemcel, in chronological order.
Reference approval
Approval date of the reference lovotibeglogene autotemcel product.
2 yr 6 mo ago
Orphan exclusivity ends
7-year orphan-drug exclusivity window.
in 4 yr 7 mo
Frequently asked questions
Are there biosimilars approved for lovotibeglogene autotemcel (LYFGENIA)?
No 351(k) biosimilars or interchangeable biosimilars referencing lovotibeglogene autotemcel are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.